The effect of semaglutide on blood pressure in patients with type-2 diabetes: a systematic review and meta-analysis.

Wu W, Tong HM, Li YS, Cui J

Endocrine15 Dec 2023Cited by 22 (Europe PMC)

PMID38097902PMCIDPMC10902041DOI10.1007/s12020-023-03636-9PepBankPUB-38097902

Summary

ObjectiveTo evaluate the blood pressure (BP) lowering ability of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), in individuals with type-2 diabetes (T2D).MethodsRandomized controlled trials (RCTs) comparing subcutaneous or oral semaglutide with placebo or other antihyperglycemic agents (AHAs) in T2D patients were identified by searching PubMed, Embase, Web of Science, ClinicalTrials.gov and Cochrane Library. These screened studies included the outcomes of interest: systolic and/or diastolic BP. Weighted mean differences (WMDs) and 95 % confidence intervals (CIs) were used to present the meta-analysis results. Pooled and sensitivity analyses were performed, and the risk of bias was evaluated.ResultsTwenty-nine RCTs with a total of 26985 participants were recruited in the final analysis. The WMD in change from baseline in systolic BP (SBP) of semaglutide versus placebo or other AHAs was -2.31 mmHg (95% CI: -3.11 to -1.51), while that for diastolic BP (DBP) was 0.09 mmHg (95% CI: -0.16 to 0.33). It also reduced glycated hemoglobin A1c (HbA1c) by 0.75% (95% CI: -0.92 to -0.58) and body weight loss by 2.80 kg (95% CI: -3.51 to -2.08). The reduction in SBP was similar for subcutaneous and oral administration of semaglutide, with -2.36 (95% CI: -3.38 to -1.35) and -2.50 (95% CI: -3.48 to -1.53), respectively.ConclusionsIn T2D, SBP decreased significantly in the semaglutide group compared with placebo or other active controls. According to the efficacy results from this meta-analysis, subcutaneous and oral semaglutide have similar SBP-reducing effects. Therefore, the treatment of T2D patients with subcutaneous semaglutide or oral preparations is beneficial for reducing SBP.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, semaglutide lowered systolic blood pressure compared with placebo or other antihyperglycemic agents.
In plain wordsIn adults with type 2 diabetes, semaglutide lowered systolic blood pressure more than placebo or other diabetes drugs.
Peptide
Semaglutide
Outcome
DecreaseChange in systolic blood pressure
Study
n = 26,985
Comparator
Placebo or other antihyperglycemic agents
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated
Measurements
Weighted mean difference, SBP change
−2.31 mmHg
semaglutide vs placebo or other AHAs
Source sentences
Summary
The WMD in change from baseline in systolic BP (SBP) of semaglutide versus placebo or other AHAs was -2.31 mmHg (95% CI: -3.11 to -1.51), while that for diastolic BP (DBP) was 0.09 mmHg (95% CI: -0.16 to 0.33).
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials (RCTs) comparing subcutaneous or oral semaglutide with placebo or other antihyperglycemic agents (AHAs) in T2D patients were identified by searching PubMed, Embase, Web of Science, ClinicalTrials.gov and Cochrane Library.
Summary · context
Twenty-nine RCTs with a total of 26985 participants were recruited in the final analysis.
Show in the study text Report a problemFND-3809790201
02HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, semaglutide did not significantly change diastolic blood pressure compared with placebo or other antihyperglycemic agents.
In plain wordsIn adults with type 2 diabetes, semaglutide did not clearly change the lower blood pressure number compared with placebo or other diabetes drugs.
Peptide
Semaglutide
Outcome
No significant changeChange in diastolic blood pressure
Study
n = 26,985
Comparator
Placebo or other antihyperglycemic agents
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated
Measurements
Weighted mean difference, DBP change
0.09 mmHg
semaglutide vs placebo or other AHAs
Source sentences
Summary
The WMD in change from baseline in systolic BP (SBP) of semaglutide versus placebo or other AHAs was -2.31 mmHg (95% CI: -3.11 to -1.51), while that for diastolic BP (DBP) was 0.09 mmHg (95% CI: -0.16 to 0.33).
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials (RCTs) comparing subcutaneous or oral semaglutide with placebo or other antihyperglycemic agents (AHAs) in T2D patients were identified by searching PubMed, Embase, Web of Science, ClinicalTrials.gov and Cochrane Library.
Summary · context
Twenty-nine RCTs with a total of 26985 participants were recruited in the final analysis.
Show in the study text Report a problemFND-3809790202
03HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, semaglutide reduced HbA1c compared with placebo or other antihyperglycemic agents.
In plain wordsIn adults with type 2 diabetes, semaglutide lowered long-term blood sugar more than placebo or other diabetes drugs.
Peptide
Semaglutide
Outcome
DecreaseChange in HbA1c
Study
n = 26,985
Comparator
Placebo or other antihyperglycemic agents
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
HbA1c reduction
0.75%
semaglutide
Source sentences
Summary
It also reduced glycated hemoglobin A1c (HbA1c) by 0.75% (95% CI: -0.92 to -0.58) and body weight loss by 2.80 kg (95% CI: -3.51 to -2.08).
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials (RCTs) comparing subcutaneous or oral semaglutide with placebo or other antihyperglycemic agents (AHAs) in T2D patients were identified by searching PubMed, Embase, Web of Science, ClinicalTrials.gov and Cochrane Library.
Summary · context
Twenty-nine RCTs with a total of 26985 participants were recruited in the final analysis.
Show in the study text Report a problemFND-3809790203
04HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, semaglutide reduced body weight compared with placebo or other antihyperglycemic agents.
In plain wordsIn adults with type 2 diabetes, people on semaglutide lost more weight than people on placebo or other diabetes drugs.
Peptide
Semaglutide
Outcome
DecreaseBody weight loss
Study
n = 26,985
Comparator
Placebo or other antihyperglycemic agents
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
Body weight loss
2.8 kg
semaglutide
Source sentences
Summary
It also reduced glycated hemoglobin A1c (HbA1c) by 0.75% (95% CI: -0.92 to -0.58) and body weight loss by 2.80 kg (95% CI: -3.51 to -2.08).
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials (RCTs) comparing subcutaneous or oral semaglutide with placebo or other antihyperglycemic agents (AHAs) in T2D patients were identified by searching PubMed, Embase, Web of Science, ClinicalTrials.gov and Cochrane Library.
Summary · context
Twenty-nine RCTs with a total of 26985 participants were recruited in the final analysis.
Show in the study text Report a problemFND-3809790204
05HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, subcutaneous semaglutide lowered systolic blood pressure compared with placebo or other antihyperglycemic agents.
In plain wordsIn adults with type 2 diabetes, injected semaglutide lowered systolic blood pressure more than placebo or other diabetes drugs.
Peptide
Semaglutide
Outcome
DecreaseChange in systolic blood pressure, subcutaneous semaglutide
Study
n: not reported in source
Comparator
Placebo or other antihyperglycemic agents
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Measurements
Systolic BP change
−2.36 mmHg
subcutaneous semaglutide
Source sentences
Summary
The reduction in SBP was similar for subcutaneous and oral administration of semaglutide, with -2.36 (95% CI: -3.38 to -1.35) and -2.50 (95% CI: -3.48 to -1.53), respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials (RCTs) comparing subcutaneous or oral semaglutide with placebo or other antihyperglycemic agents (AHAs) in T2D patients were identified by searching PubMed, Embase, Web of Science, ClinicalTrials.gov and Cochrane Library.
Summary · context
Twenty-nine RCTs with a total of 26985 participants were recruited in the final analysis.
Show in the study text Report a problemFND-3809790205
06HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, oral semaglutide lowered systolic blood pressure compared with placebo or other antihyperglycemic agents.
In plain wordsIn adults with type 2 diabetes, oral semaglutide lowered systolic blood pressure more than placebo or other diabetes drugs.
Peptide
Semaglutide
Outcome
DecreaseChange in systolic blood pressure, oral semaglutide
Study
n: not reported in source
Comparator
Placebo or other antihyperglycemic agents
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · oralAs given in this study (human).
Measurements
Systolic BP change
−2.5 mmHg
oral semaglutide
Source sentences
Summary
The reduction in SBP was similar for subcutaneous and oral administration of semaglutide, with -2.36 (95% CI: -3.38 to -1.35) and -2.50 (95% CI: -3.48 to -1.53), respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials (RCTs) comparing subcutaneous or oral semaglutide with placebo or other antihyperglycemic agents (AHAs) in T2D patients were identified by searching PubMed, Embase, Web of Science, ClinicalTrials.gov and Cochrane Library.
Summary · context
Twenty-nine RCTs with a total of 26985 participants were recruited in the final analysis.
Show in the study text Report a problemFND-3809790206

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.